Generalized Reciprocals, Factors of Dickson Polynomials and Generalized Cyclotomic Polynomials over Finite Fields

We give new descriptions of the factors of Dickson polynomials over finite fields in terms of cyclotomic factors. To do this generalized reciprocal polynomials are introduced and characterized. We also study the factorization of generalized cyclotomic polynomials and their relationship to the factorization of Dickson polynomials

Irreducible Polynomials over GF(2) with Three Prescribed Coefficients

For an odd positive integer n, we determine formulas for the number of irreducible polynomials of degree n over GF(2) in which the coefficients of xn-1, xn-2 and xn-3 are specified in advance. Formulas for the number of elements in GF(2n) with the first three traces specified are also given

Pencils of Quadratic Forms over Finite Fields

A formula for the number of common zeros of a non-degenerate pencil of quadratic forms is given. This is applied to pencils which count binary strings with an even number of 1\u27s prescribed distances apart

Sums of Gauss Sums and Weights of Irreducible Codes

We develop a matrix approach to compute a certain sum of Gauss sums which arises in the study of weights of irreducible codes. A lower bound on the minimum weight of certain irreducible codes is given

Explicit Factorizations of Cyclotomic and Dickson Polynomials over Finite Fields

We give, over a finite field Fq, explicit factorizations into a product of irreducible polynomials, of the cyclotomic polynomials of order 3·2n, the Dickson polynomials of the first kind of order 3·2n and the Dickson polynomials of the second kind of order 3·2n  − 1

Factors of Dickson Polynomials over Finite Fields

We give new descriptions of the factors of Dickson polynomials over finite fields

Effective Use of Mass Spectrometry in the Clinical Laboratory.

BackgroundHistorically the success of mass spectrometry in the clinical laboratory has focused on drugs of abuse confirmations, newborn screening, and steroid analysis. Clinical applications of mass spectrometry continue to expand, and mass spectrometry is now being used in almost all areas of laboratory medicine.ContentA brief background of the evolution of mass spectrometry in the clinical laboratory is provided with a discussion of future applications. Prominent examples of mass spectrometry are covered to illustrate how it has improved the practice of medicine and enabled physicians to provide better patient care. With increasing economic pressures and decreasing laboratory test reimbursement, mass spectrometry testing has been shown to provide cost-effective solutions. In addition to pointing out the numerous benefits, the challenges of implementing mass spectrometry in the clinical laboratory are also covered.SummaryMass spectrometry continues to play a prominent role in the field of laboratory medicine. The advancement of this technology along with the development of new applications will only accelerate the incorporation of mass spectrometry into more areas of medicine

Products Liability

The authors discuss recent developments in Florida law in the area of products liability. The distinctions between the three theories of recovery in products liability actions, negligence, implied warranty and strict liability, are clarified through close and detailed analysis. The authors prefer strict liability to the other two causes of action because of its lessened burden of proof on plaintiffs and its less intricate analysis. The examination of case law, however, leads the authors to conclude that the courts are often applying the strict liability doctrine incorrectly

Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel beta-coronavirus that has recently emerged as the cause of the 2019 coronavirus pandemic (COVID-19). Polymerase chain reaction (PCR) based tests are optimal and recommended for the diagnosis of an acute SARS-CoV-2 infection. Serology tests for viral antibodies provide an important tool to diagnose previous exposure to the virus. Here we evaluate the analytical performance parameters of the Diazyme SARS-CoV-2 IgM/IgG serology assays and describe the kinetics of IgM and IgG seroconversion observed in patients with PCR-confirmed COVID-19 who were admitted to our hospital.MethodsWe validated the performance of the Diazyme assay in 235 presumed SARS-CoV-2 negative subjects to determine specificity. Subsequently, we evaluated the SARS-CoV-2 IgM and IgG seroconversion of 54 PCR-confirmed COVID-19 patients and determined sensitivity of the assay at three different timeframes.ResultSensitivity and specificity for detecting seropositivity at ≥15 days following a positive SARS-CoV-2 PCR result, was 100.0% and 98.7% when assaying for the panel of IgM and IgG. The median time to seropositivity observed for a reactive IgM and IgG result from the date of a positive PCR was 5 days (IQR: 2.75-9 days) and 4 days (IQR: 2.75-6.75 days), respectively.ConclusionsOur data demonstrate that the Diazyme IgM/IgG assays are suited for the purpose of detecting SARS-CoV-2 IgG and IgM in patients with suspected SARS-CoV-2 infections. For the first time, we report longitudinal data showing the evolution of seroconversion for both IgG and IgM in a cohort of acutely ill patients in the United States. We also demonstrate a low false positive rate in patients who were presumed to be disease free

False-positive interferences of common urine drug screen immunoassays: a review.

Urine drug screen (UDS) immunoassays are a quick and inexpensive method for determining the presence of drugs of abuse. Many cross-reactivities exist with other analytes, potentially causing a false-positive result in an initial drug screen. Knowledge of these potential interferents is important in determining a course of action for patient care. We present an inclusive review of analytes causing false-positive interferences with drugs-of-abuse UDS immunoassays, which covers the literature from the year 2000 to present. English language articles were searched via the SciFinder platform with the strings 'false positive [drug] urine' yielding 173 articles. These articles were then carefully analyzed and condensed to 62 that included data on causes of false-positive results. The discussion is separated into six sections by drug class with a corresponding table of cross-reacting compounds for quick reference. False-positive results were described for amphetamines, opiates, benzodiazepines, cannabinoids, tricyclic antidepressants, phencyclidine, lysergic acid diethylamide and barbiturates. These false-positive results support the generally accepted practice that immunoassay positive results are considered presumptive until confirmed by a second independent chemical technique